SCHEMBL5116111

SCHEMBL5116111

COc1cccc(C2=NOC3(CCN(C(=O)Nc4cccc(C)c4)CC3)C2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.55
HTT P42858 2/20 0.52
RAB9A P51151 3/20 0.51
NPC1 O15118 1/20 0.51
ALDH1A1 P00352 3/20 0.49
MAPK1 P28482 3/20 0.48
MAPT P10636 3/20 0.48
GAA P10253 1/20 0.47
GFER P55789 1/20 0.47
TUBB4A P04350 1/20 0.47
TUBB P07437 1/20 0.47
TUBA3C P0DPH7 1/20 0.47
TUBA1B P68363 1/20 0.47
TUBA4A P68366 1/20 0.47
TUBB4B P68371 1/20 0.47
TUBB3 Q13509 1/20 0.47
TUBB2A Q13885 1/20 0.47
TUBB8 Q3ZCM7 1/20 0.47
TUBA3E Q6PEY2 1/20 0.47
TUBA1A Q71U36 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5124433 0.94 SMN1; SMN2 (0.61) SMN1; SMN2HTTRAB9ANPC1ALDH1A1
SCHEMBL5130018 0.92 SMN1; SMN2 (0.51) SMN1; SMN2HTTRAB9ANPC1ALDH1A1
SCHEMBL5121286 0.92 SMN1; SMN2 (0.55) SMN1; SMN2HTTRAB9ANPC1ALDH1A1
SCHEMBL5116074 0.91 SMN1; SMN2 (0.57) SMN1; SMN2HTTRAB9ANPC1ALDH1A1
SCHEMBL5119726 0.91 SMN1; SMN2 (0.59) SMN1; SMN2HTTRAB9ANPC1ALDH1A1
SCHEMBL5125858 0.90 SMN1; SMN2 (0.54) SMN1; SMN2HTTRAB9ANPC1ALDH1A1
SCHEMBL5129910 0.90 SMN1; SMN2 (0.56) SMN1; SMN2HTTRAB9ANPC1ALDH1A1
SCHEMBL5121555 0.90 CYP1A2 (0.57) SMN1; SMN2HTTRAB9ANPC1ALDH1A1
SCHEMBL5130656 0.90 CYP2D6 (0.54) SMN1; SMN2HTTRAB9ANPC1ALDH1A1
SCHEMBL5120071 0.89 ALDH1A1 (0.54) HTTRAB9AALDH1A1MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1888596-B1 SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF MEDICAMENTS GRUENENTHAL GMBH (DE) 2014-10-22 EP claimed
US-8772307-B2 Substituted spiro compounds and their use for producing pain-relief medicaments GRUENENTHAL GMBH (DE) 2014-07-08 US claimed
US-20080269271-A1 Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders GRUENENTHAL GMBH (DE) 2008-10-30 US claimed
US-20080269271-A1 Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders GRUENENTHAL GMBH (DE) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269271-A1 Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders INA, SCN1A, SI SMN1; SMN2 79/4885HTT 50/4885RAB9A 2540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.